MICHELLE TAYLOR: Open Payments
NPI 1023469244 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,004 in 152 payments from 25 companies in 2025. Trend: 2023 $2,846 · 2024 $2,648 · 2025 $3,004
Food & beverage: $2,871Education: $133
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 26 | $611 |
| United Therapeutics Corporation | 11 | $236 |
| Grifols USA, LLC | 10 | $232 |
| GlaxoSmithKline, LLC. | 19 | $221 |
| Actelion Pharmaceuticals US, Inc. | 6 | $193 |
| Verona Pharma, Inc. | 12 | $192 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $182 |
| Merck Sharp & Dohme LLC | 7 | $173 |
| GENZYME CORPORATION | 10 | $167 |
| ANI Pharmaceuticals, Inc. | 7 | $139 |
Products named: DUPIXENT, FASENRA, Prolastin-C Liquid, TEZSPIRE, Ohtuvayre, Tyvaso, PURIFIED CORTROPHIN GEL, NUCALA.
Industry payments across MS — which companies pay providers there.
